Tocilizumab for juvenile idiopathic arthritis: a single-center case series

Yazılıtaş, Fatma; Özdel, Semanur; Şimşek, Doğan; Aydoğ, Özlem; Çakıcı, Evrim Kargın; Can, Gökçe; Güngör, Tülin; Bülbül, Mehmet

doi:10.1590/1516-3180.2018.0489220719

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of our patients experienced TCZ possibly related elevated transaminases, macrophage activation syndrome (MAS), hyperlipidemia, malignancy, autoimmune diseases, or deaths, which is consistent with previous reports [8,13,15,27].…”

Section: Discussionsupporting

confidence: 93%

“…As mentioned in several studies, infection is the most frequently revealed side effect of TCZ use [13,23,25]. Contrary to expectations, none of our patients developed TCZ possibly related significant infections.…”

Section: Discussioncontrasting

confidence: 89%

“…Interestingly, the effectiveness of TCZ in both sJIA and pJIA has been exemplified in other reports using variable scores [8,10,11,13,26,27].…”

Section: Discussionmentioning

confidence: 74%

“…TCZ has been approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for both sJIA and pJIA pediatric patients above 2 years of age [12]. TCZ is reported as an efficient drug that reduces active manifestations in JIA patients and improves their life quality [13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

Muzaffer

Abdelgalil

2021

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disorder. Progress in modalities of therapy improves the disease outcome. We aimed to determine the efficacy and safety of tocilizumab (TCZ) in the management of systemic (sJIA) and polyarticular (pJIA) in children who are resistant to conventional as well as other biological therapies. In this retrospective study, we selected JIA patients according to the International League of Association for Rheumatology (ILAR) criteria and were treated with TCZ. Response to TCZ was assessed using Juvenile Arthritis Disease Activity Score-10 (JADAS-10) and also outcomes were assessed according to the American College of Rheumatology (ACR) remission criteria. Safety of the drug was assessed by documenting possibly related adverse effects (AE). Statistical analysis using SPSS version 25 with statistical significance is considered if p ≤ 0.05. We included 16 JIA patients aged ≤ 18 years but 2 of them were excluded as they developed severe reaction during the TCZ 1st dose, so finally, 14 patients were included. Results The median age of our patients was 12 years. Of these 14 patients, 9 (64.3%) had sJIA and 5 (35.7%) had pJIA. TCZ use led to significant improvement in the JADAS-10 from mean 22.4 (± 7.9) when it was initially assessed and then 3, 6, 12, and 24 months after TCZ initiation with means 5.7 (± 3.9), 4.4 (± 3.7), 3.5 (± 3.1), and 2.7 (± 2.2), (P = 0.001, 0.001, 0.005, 0.012), respectively. Five patients exhibited TCZ possibly expected side effects. Neutropenia and infusion-related reactions were the most frequent AE. Conclusions Tocilizumab seems to be generally effective and safe drug in the management of sJIA and pJIA especially in cases refractory to conventional as well as other biologic agents.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussioncontrasting

confidence: 89%

“…Interestingly, the effectiveness of TCZ in both sJIA and pJIA has been exemplified in other reports using variable scores [8,10,11,13,26,27].…”

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

Muzaffer

Abdelgalil

2021

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

show abstract

“…DMARDs normally used in RA do not always offer satisfactory results. Recently, though, TCZ has been tested in this population and results have been encouraging, demonstrating the central role of IL-6 in autoimmune diseases [ 91 ].…”

Section: Targeting Interleukin-6: Available Optionsmentioning

confidence: 99%

Interleukin-6 in Rheumatoid Arthritis

Pandolfi

Franza

Carusi

et al. 2020

IJMS

147

View full text Add to dashboard Cite

The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.

show abstract

Research progress in drug therapy of juvenile idiopathic arthritis

Zhao

Deng

2022

World J Pediatr

View full text Add to dashboard Cite

Tocilizumab for juvenile idiopathic arthritis: a single-center case series

Cited by 5 publications

References 27 publications

Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

Interleukin-6 in Rheumatoid Arthritis

Research progress in drug therapy of juvenile idiopathic arthritis

Contact Info

Product

Resources

About